A Single Amino Acid Residue Defines the Difference in Ovalicin Sensitivity Between Type I and II Methionine Aminopeptidases

Overview

Journal J Biol Chem

Specialty Biochemistry

Date 2003 Dec 17

PMID 14676204

Citations 9

Authors

Cathleen M Brdlik

Craig M Crews

Affiliations

Soon will be listed here.

Abstract

TNP-470, the first anti-angiogenic small molecule to enter clinical trials, targets methionine aminopeptidase-2 (MetAP-2), a metalloprotease that cleaves the N-terminal methionine of proteins. Previously, biochemical binding, in vivo yeast studies, and structural studies of human methionine aminopeptidase-2 bound to TNP-470 and its analogs fumagillin and ovalicin revealed that these compounds exhibit specificity for MetAP-2 over its family member MetAP-1. To further elucidate the nature of this specificity, we developed a yeast-based screen for human MetAP-2 mutations that confer ovalicin resistance. Of the three resistant alleles, A362T appeared in the majority of clones and was found to be the most resistant to the ovalicin class of inhibitors. Alignment of human MetAP-2 with human MetAP-1, which is naturally ovalicin-resistant, revealed that the analogous residue in MetAP-1 is also a threonine. Mutation of this residue to alanine resulted in an ovalicin-sensitive MetAP-1 allele, demonstrating that an alanine at this position is critical for inhibition by ovalicin. These results provide a molecular explanation for the specificity exhibited by this class of anti-angiogenic agents for MetAP-2 over MetAP-1 and may prove useful in the development of additional MetAP-2-specific therapeutic agents.

Citing Articles

Advances in Bacterial Methionine Aminopeptidase Inhibition.

Helgren T, Wangtrakuldee P, Staker B, Hagen T Curr Top Med Chem. 2015; 16(4):397-414.

PMID: 26268344 PMC: 5009474. DOI: 10.2174/1568026615666150813145410.

Synergistic effect of antiangiogenic nanotherapy combined with methotrexate in the treatment of experimental inflammatory arthritis.

Zhou H, Hu G, Wickline S, Lanza G, Pham C Nanomedicine (Lond). 2010; 5(7):1065-74.

PMID: 20874021 PMC: 3035945. DOI: 10.2217/nnm.10.78.

Reversal of TNP-470-induced endothelial cell growth arrest by guanine and guanine nucleosides.

Hines J, Ju R, Dutschman G, Cheng Y, Crews C J Pharmacol Exp Ther. 2010; 334(3):729-38.

PMID: 20571059 PMC: 2939662. DOI: 10.1124/jpet.110.169110.

Structure of a microsporidian methionine aminopeptidase type 2 complexed with fumagillin and TNP-470.

Alvarado J, Nemkal A, Sauder J, Russell M, Akiyoshi D, Shi W Mol Biochem Parasitol. 2009; 168(2):158-67.

PMID: 19660503 PMC: 2759695. DOI: 10.1016/j.molbiopara.2009.07.008.

System for expression of microsporidian methionine amino peptidase type 2 (MetAP2) in the yeast Saccharomyces cerevisiae.

Upadhya R, Zhang H, Weiss L Antimicrob Agents Chemother. 2006; 50(10):3389-95.

PMID: 16917013 PMC: 1610073. DOI: 10.1128/AAC.00726-06.

References

Schiestl R, Gietz R . High efficiency transformation of intact yeast cells using single stranded nucleic acids as a carrier. Curr Genet. 1989; 16(5-6):339-46. DOI: 10.1007/BF00340712. View

Martin G, Viskochil D, Bollag G, McCabe P, Crosier W, Haubruck H . The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell. 1990; 63(4):843-9. DOI: 10.1016/0092-8674(90)90150-d. View

Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H . Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature. 1990; 348(6301):555-7. DOI: 10.1038/348555a0. View

Kusaka M, Sudo K, Fujita T, Marui S, Itoh F, Ingber D . Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent. Biochem Biophys Res Commun. 1991; 174(3):1070-6. DOI: 10.1016/0006-291x(91)91529-l. View

Muhlrad D, Hunter R, Parker R . A rapid method for localized mutagenesis of yeast genes. Yeast. 1992; 8(2):79-82. DOI: 10.1002/yea.320080202. View

Chang Y, Teichert U, Smith J . Molecular cloning, sequencing, deletion, and overexpression of a methionine aminopeptidase gene from Saccharomyces cerevisiae. J Biol Chem. 1992; 267(12):8007-11. View

Roderick S, Matthews B . Structure of the cobalt-dependent methionine aminopeptidase from Escherichia coli: a new type of proteolytic enzyme. Biochemistry. 1993; 32(15):3907-12. DOI: 10.1021/bi00066a009. View

Peacock D, Banquerigo M, Brahn E . A novel angiogenesis inhibitor suppresses rat adjuvant arthritis. Cell Immunol. 1995; 160(2):178-84. DOI: 10.1016/0008-8749(95)80025-e. View

Mumberg D, Muller R, Funk M . Yeast vectors for the controlled expression of heterologous proteins in different genetic backgrounds. Gene. 1995; 156(1):119-22. DOI: 10.1016/0378-1119(95)00037-7. View

10.

OReilly M, Brem H, Folkman J . Treatment of murine hemangioendotheliomas with the angiogenesis inhibitor AGM-1470. J Pediatr Surg. 1995; 30(2):325-9; discussion 329-30. DOI: 10.1016/0022-3468(95)90583-9. View

11.

ARFIN S, Kendall R, Hall L, Weaver L, Stewart A, Matthews B . Eukaryotic methionyl aminopeptidases: two classes of cobalt-dependent enzymes. Proc Natl Acad Sci U S A. 1995; 92(17):7714-8. PMC: 41216. DOI: 10.1073/pnas.92.17.7714. View

12.

Li X, Chang Y . Amino-terminal protein processing in Saccharomyces cerevisiae is an essential function that requires two distinct methionine aminopeptidases. Proc Natl Acad Sci U S A. 1995; 92(26):12357-61. PMC: 40356. DOI: 10.1073/pnas.92.26.12357. View

13.

Sin N, Meng L, Wang M, Wen J, Bornmann W, Crews C . The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc Natl Acad Sci U S A. 1997; 94(12):6099-103. PMC: 21008. DOI: 10.1073/pnas.94.12.6099. View

14.

Griffith E, Su Z, Turk B, Chen S, Chang Y, Wu Z . Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin. Chem Biol. 1997; 4(6):461-71. DOI: 10.1016/s1074-5521(97)90198-8. View

15.

Dezube B, Von Roenn J, Holden-Wiltse J, Cheung T, Remick S, Cooley T . Fumagillin analog in the treatment of Kaposi's sarcoma: a phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team. J Clin Oncol. 1998; 16(4):1444-9. DOI: 10.1200/JCO.1998.16.4.1444. View

16.

Lowther W, McMillen D, Orville A, Matthews B . The anti-angiogenic agent fumagillin covalently modifies a conserved active-site histidine in the Escherichia coli methionine aminopeptidase. Proc Natl Acad Sci U S A. 1998; 95(21):12153-7. PMC: 22800. DOI: 10.1073/pnas.95.21.12153. View

17.

Liu S, Widom J, Kemp C, Crews C, Clardy J . Structure of human methionine aminopeptidase-2 complexed with fumagillin. Science. 1998; 282(5392):1324-7. DOI: 10.1126/science.282.5392.1324. View

18.

Griffith E, Su Z, NIWAYAMA S, Ramsay C, Chang Y, Liu J . Molecular recognition of angiogenesis inhibitors fumagillin and ovalicin by methionine aminopeptidase 2. Proc Natl Acad Sci U S A. 1998; 95(26):15183-8. PMC: 28017. DOI: 10.1073/pnas.95.26.15183. View

19.

Kudelka A, Levy T, Verschraegen C, Edwards C, Piamsomboon S, Termrungruanglert W . A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. Clin Cancer Res. 1998; 3(9):1501-5. View

20.

Stadler W, Kuzel T, Shapiro C, Sosman J, Clark J, Vogelzang N . Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J Clin Oncol. 1999; 17(8):2541-5. DOI: 10.1200/JCO.1999.17.8.2541. View